Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

Annals of Neurology

Volumn 39, Issue 1, 1996, Pages 37-45

  Penney Jr , John B ^a,i   Oakes, David ^b   Shoulson, Ira ^b   Fahn, Stanley ^c   Lang, Anthony ^d   William Langston, J ^e   LeWitt, Peter ^f   Warren Olanow, C ^g   Tanner, Caroline ^h   Kieburtz, Karl ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c New York State Psychiat Inst and New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e PARKINSON S INSTITUTE   (United States)

^f SINAI GRACE HOSPITAL   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CARBIDOPA; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISABILITY; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; TREATMENT OUTCOME;

AGED; ANTIOXIDANTS; ANTIPARKINSON AGENTS; DISABLED PERSONS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; SELEGILINE; TREATMENT OUTCOME; VITAMIN E;

EID: 9044226896     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390107     Document Type: Article

References (38)

1. Cotzias GC, Papavasiliou PS, Gellen R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280:337-345
2. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Ann Intern Med 1975;83:456-463
3. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980;195:283-293
4. Hoehn MM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand 1985;71:97-106
5. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1:292-296
6. Fahn S. On-off phenomenon with levodopa therapy in parkinsonism. Neurology 1974;34:431-441
7. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260
8. Pederzoli M, Girotti F, Scigliano G, et al. L-Dopa long term treatment in Parkinson's disease: age-related side effects. Neurology 1983;33:1518-1522
9. Diamond S, Markham C, Hoehn M, et al. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12
10. Blin J, Bonnet A-M, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416
11. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41-622-629
12. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384
13. Birkmayer W. Deprenyl (Selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand 1983;suppl 95:103-106
14. Parkinson Study Group. Effect of deptenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371
15. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989;26:689-690
16. Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness. Ann NY Acad Sci 1989,570:186-196
17. Acosta D, Kass IS, Cottrell JE. Effect of alpha-tocopherol and free radicals on anoxic damage in the rat hippocampal slice. Exp Neurol 1987;97:607-614
18. Parkinson Study Group DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46:1052-1060
19. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36
20. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford, England: Blackwell, 1987:205
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34:585-612
22. Cox DR, Oakes D. Analysis of survival data. In: Monographs on statistics and applied probability, vol 21. London: Chapman and Hall, 1984, chap 7
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
24. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
25. Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 1986;46:1359-1365
26. + in vivo. Eur J Pharmacol 1993; 243:241-247
27. Ansati KS, Yu PH, Kruck TP, Tatton WG. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053
28. Halliwell B, Gutteridge JMC. Oxygen radicals and the nervous system. Trends Neurosci 1985;8:22-26
29. Landau WM. Clinical neuromythology IX: pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 1990;40: 1337-1339
30. Schulzer M, Mak E, Calne DB. The antiparkinsonian efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992,32:795-798
31. Ward CD. Does Selegiline delay progression of Parkinson's disease? A critical reevaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57:217-220
32. Oakes D. Antiparkinson efficacy of deprenyl. Ann Neurol 1993;34:634
33. Wu RM, Chiu HC, Wang M, Chen RC. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993; 5:127-133
34. Van Hartesveld C, Joyce JN. Effect of estrogen on the basal ganglia. Neurosci Biobehav Rev 1986;10:1-14
35. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-371
36. Mouradian MM, Juncos JL, Schlegel J, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378
37. Narabayashi H, Kondo T, Nagatsu T, et al. DL-threo-3,4-Dihydroxyphenylserine for freezing symptoms in parkinsonism. In: Hassler RG, Christ JF, eds. Parkinson-specific motor and mental disorders, role of the pallidum: pathophysiological, biochemical and therapeutic aspects. Advances in neurology, vol 40. New York: Raven Press, 1984:497-507
38. Narabayashi H, Kondo T, Yokochi F, Nagatsu T. Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia. In: Yahr MD, Bergman KJ, eds. Advances in neurology, vol 45. Parkinson's disease. New York: Raven Press, 1986:593-602